The Pershing Square Foundation (PSF) is a family foundation established in 2006 to support exceptional leaders and innovative organizations that tackle important social issues and deliver scalable and sustainable global impact. PSF has committed more than $600 million in grants and social investments in target areas including health and medicine, education, economic development and social justice. Bill Ackman and Neri Oxman are co-trustees of the Foundation.
By investing in pioneering individuals, non-profits and mission driven companies who dare to re-imagine the possible, PSF has helped to bring about important breakthroughs — from cancer research and small scale agriculture to criminal justice reform and educational opportunities for young people in communities — around the world.
Link to Pershing Square flip book
The Pershing Square Sohn Cancer Research Alliance was formed in 2013 by The Pershing Square Foundation, which has since committed more than $40 million to 66 scientists, in partnership with The Sohn Conference Foundation. The Alliance is dedicated to playing a catalytic role in accelerating cures for cancer by supporting innovative cancer research and by facilitating collaborations between academia and industry. Annually, the Alliance awards the
Pershing Square Sohn Prize for Young Investigators in Cancer Research ($750,000 over three years) to early-career, greater New York City area scientists who are engaged in cutting-edge cancer research. For more information, visit http://psscra.org/.
The application portal for the 2024 Pershing Square Sohn Prize for Young Investigators in Cancer Research is now closed. The deadline to submit a Letter of Intent was Monday, October 30, 2023 by 5:00pm EST.
Please check back in early summer 2024 for information on our 2025 application cycle.
If you have any questions regarding the Pershing Square Sohn Prize, please contact us at email@example.com.
The Pershing Square Foundation’s brain initiative funds cutting-edge research that revolutionizes our ability to predict, prevent, and treat neurodegenerative diseases (NDDs). Advancing our fundamental understanding of the brain and cognition to ultimately combat neurodegeneration and related diseases is a goal of increasing urgency. Breakthroughs in basic scientific and translational research will yield critical tools for and knowledge of NDDs, including Alzheimer’s Disease and Dementia, which affect millions of people worldwide.
The MIND (Maximizing Innovation in Neuroscience Discovery) Prize ($750,000 over three years) supports and empowers early-to-mid-career investigators to rethink conventional paradigms around NDDs. Modeled after the Pershing Square Sohn Prize for Young Investigators in Cancer Research, the MIND Prize catalyzes interdisciplinary approaches and facilitate collaborations across academic departments and institutions. It fuels the groundbreaking research that will accelerate our understanding of NDDs at every level.
Projects may range from the invention of novel tools, techniques, and technologies for mapping and analyzing the brain to bold approaches that demonstrate extraordinary therapeutic potential. Research domains may include—but are not limited to—neurobiology, brain imaging and mapping, machine learning, drug delivery, and synthetic biology.
We are currently accepting applications for the 2024 MIND Prize. The deadline to submit a Letter of Intent application is Monday, November 13, 2023 by 5:00pm EST.